Darrell Borger
Darrell Borger
Massachusetts General Hospital
Verified email at mgh.harvard.edu
Cited by
Cited by
Frequent mutation of isocitrate dehydrogenase (IDH) 1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping
DR Borger, KK Tanabe, KC Fan, HU Lopez, VR Fantin, KS Straley, ...
The oncologist 17 (1), 72, 2012
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
LV Sequist, RS Heist, AT Shaw, P Fidias, R Rosovsky, JS Temel, ...
Annals of Oncology 22 (12), 2616-2624, 2011
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
D Dias‐Santagata, S Akhavanfard, SS David, K Vernovsky, G Kuhlmann, ...
EMBO molecular medicine 2 (5), 146-158, 2010
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
MJ Niederst, LV Sequist, JT Poirier, CH Mermel, EL Lockerman, ...
Nature communications 6 (1), 1-10, 2015
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non–small-cell lung cancer
LV Sequist, S Gettinger, NN Senzer, RG Martins, PA Jšnne, R Lilenbaum, ...
Journal of clinical oncology 28 (33), 4953, 2010
BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications
D Dias-Santagata, Q Lam, K Vernovsky, N Vena, JK Lennerz, DR Borger, ...
PloS one 6 (3), e17948, 2011
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma
AX Zhu, TA Abrams, R Miksad, LS Blaszkowsky, JA Meyerhardt, H Zheng, ...
Cancer 117 (22), 5094-5102, 2011
A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non–small-cell lung cancer
Z Su, D Dias-Santagata, MK Duke, K Hutchinson, YL Lin, DR Borger, ...
The Journal of Molecular Diagnostics 13 (1), 74-84, 2011
Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas
H Wakimoto, S Tanaka, WT Curry, F Loebel, D Zhao, K Tateishi, J Chen, ...
Clinical cancer research 20 (11), 2898-2909, 2014
Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer
EL Kwak, LG Ahronian, G Siravegna, B Mussolin, DR Borger, JT Godfrey, ...
Cancer discovery 5 (12), 1271-1281, 2015
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response
AT Fathi, H Sadrzadeh, DR Borger, KK Ballen, PC Amrein, EC Attar, ...
Blood, The Journal of the American Society of Hematology 120 (23), 4649-4652, 2012
EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas
RJH Ryan, M Nitta, D Borger, LR Zukerberg, JA Ferry, NL Harris, ...
PloS one 6 (12), e28585, 2011
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma
DR Borger, L Goyal, T Yau, RT Poon, M Ancukiewicz, V Deshpande, ...
Clinical Cancer Research 20 (7), 1884-1890, 2014
Acquired resistance to crizotinib in NSCLC with MET exon 14 skipping
RS Heist, LV Sequist, D Borger, JF Gainor, RS Arellano, LP Le, ...
Journal of Thoracic Oncology 11 (8), 1242-1245, 2016
Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets
AX Zhu, DR Borger, Y Kim, D Cosgrove, A Ejaz, S Alexandrescu, ...
Annals of surgical oncology 21 (12), 3827-3834, 2014
Activation of PI3K signaling in Merkel cell carcinoma
V Nardi, Y Song, JA Santamaria-Barria, AK Cosper, Q Lam, AC Faber, ...
Clinical Cancer Research 18 (5), 1227-1236, 2012
Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment
V Nardi, PM Sadow, D Juric, D Zhao, AK Cosper, K Bergethon, ...
Clinical cancer research 19 (2), 480-490, 2013
Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma
L Goyal, A Govindan, RA Sheth, V Nardi, LS Blaszkowsky, JE Faris, ...
The oncologist 20 (9), 1019, 2015
A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal†…
TS Hong, DP Ryan, DR Borger, LS Blaszkowsky, BY Yeap, ...
International Journal of Radiation Oncology* Biology* Physics 89 (4), 830-838, 2014
Induction of heme oxygenase-1 (HSP32) mRNA in skeletal muscle following contractions
DA Essig, DR Borger, DA Jackson
American Journal of Physiology-Cell Physiology 272 (1), C59-C67, 1997
The system can't perform the operation now. Try again later.
Articles 1–20